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	 The	aim	of	 this	work	was	to	develop	and	validate	a	simple,	sensitive	and	rapid	method	for
the	 quantitation	 of	 levetiracetam	 (LEV)	 in	 plasma	 using	 LC‐Tandem	 mass	 spectrometry.
Plasma	 samples	were	prepared	by	 simple	protein	precipitation	 using	 acetonitrile;	 atenolol
was	 used	 as	 internal	 standard	 (IS).	 Chromatographic	 separation	 was	 done	 on	 Luna	 5	µm
C18(2)	(Phenomenex)	50	×	2.0	mm	using	gradient	flow	using	solvent	A	(0.1%	formic	acid)
and	 solvent	 B	 (0.1%	 formic	 acid	 in	 acetonitrile:	 water,	 95:5,	 v:v).	 The	 positive‐ion	 mass
spectrometric	 detection	method	 utilized	 electrospray	 ionization	 and	 the	multiple	 reaction
monitoring	 (MRM)	mode.	The	MRM	ion	 transitions	were170.9	→	140.8	and	267.3	→	145.1
for	levetiracetam	and	atenolol,	respectively.	The	retention	time	of	levetiracetam	and	atenolol
is	 3.24	 and	 2.96	min,	 respectively.	 The	 total	 run	 time	was	 5	min.	The	 assay	was	 validated
over	a	concentration	range	 from	1	to	100	µg/mL.	The	method	was	robust	(minimal	matrix
effect),	sensitive	(LOQ,	1	µg/mL)	metabolites	and	reproducible	(The	precision	and	accuracy
for	both	intra‐	and	inter‐day	were	acceptable	<15%).	The	method	can	be	done	on	traditional
LC‐MS	 equipment.	 The	method	was	 effectively	 applied	 to	 single	 case	 study	 receiving	 toxic
dose	of	LEV.	
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1.	Introduction	
	
Epilepsy	is	a	complicated	disorder	characterized	by	two	or	
more	unexplained	seizures.	Epilepsy	is	classified	according	to	
the	origin	of	seizure	into	partial	and	generalized	seizures	[1,2].	
The	 strategy	of	 treatment	 of	 the	 epilepsy	varies	 according	 to	
seizure	 type	and	 the	epileptic	 syndrome	 [3].	First	 generation	
antiepileptic	 drugs	 as	 phenytoin,	 carbamazepine	 and	 sodium	
valproate	are	widely	used,	however	because	of	their	high	risk	
of	 adverse	 reactions	 and	 drug	 interactions;	 they	 require	
therapeutic	 monitoring	 [4].	 On	 the	 other	 hand	 second	 gene‐
ration	drugs	are	preferred	due	to	favourable	side	effect	profile	
and	less	chance	of	drug	interactions	[5].	
Levetiracetam	 (LEV)	 is	 a	 brand	 new	 antiepileptic	 drug	
Figure	 1.	 It	 is	widely	 distributed	 since	 2000.	 It	 is	 belongs	 to	
second	 generation	 antiepileptic	 drugs.	 Levetiracetam	 effect‐
tively	 used	 for	 other	 psychiatric	 and	 neurologic	 symptoms	
such	 as	 Tourette	 syndrome,	 autism,	 as	 well	 as	 anxiety	
disorders.	 At	 present,	 little	 is	 known	 concerning	 the	 mecha‐
nism	 of	 antiepileptic	 action	 [6].	 Numerous	 chromatographic	
methods	have	been	described	for	the	quantification	of	LEV	in	
biological	 fluids.	Most	 of	 these	methods	 are	utilized	different	
chromatographic	techniques	such	as	Gas	chromatography	(GC)	
with	nitrogen‐phosphorus	detection,	High	performance	liquid	
chromatography	(HPLC)	and	GC‐MS	[7,8].	There	are	numerous	
HPLC	 techniques	 [9‐16],	 however	 there	 are	 few	 reported	
methods	for	the	analysis	of	LEV	using	LC‐MS/MS	[17‐20].	Two	
of	 which	 utilize	 a	 tedious	 solid	 phase	 extraction	 (SPE)	
procedure	of	sample	extraction	[17,19].	
	
LEV		
	
				ATN,	IS	
	
Figure	1.	Chemical	structure	of	levetiracetam	(LEV)	and	internal	standard,	
atenolol	(ATN,	IS).	
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The	 objective	 of	 the	 present	 report	 was	 to	 develop	 and	
validate	 a	 suitable	 LC‐Tandem	 mass	 method	 for	 moderate	
throughput	as	in	clinical	or	commercial	reference	laboratories	
for	therapeutic	drug	monitoring	of	LEV.	
				
2.	Experimental	
	
2.1.	Materials	and	reagents	
	
Levetiracetam	 and	 atenolol	 were	 purchased	 from	 Sigma‐
Aldrich	 Corporation	 (St	 Louis,	 MO,	 USA).	 All	 solvents	 were	
HPLC	 grade	 and	 were	 obtained	 from	 Merck	 (Kilsyth,	 VIC,	
Australia).	 Blank	 plasma	 was	 obtained	 from	 Australian	 Red	
Cross.		
	
2.2.	Equipment	
	
The	HPLC	apparatus	consisted	of	 two	Shimadzu	LC‐10AD	
pumps,	auto	sampler	Shimadzu	SIL‐20AC‐HT	and	a	Shimadzu	
SLC‐10A	VP	system	controller.	Detection	was	performed	using	
a	 MDS	 Sciex	 API2000	 triple	 quadrupole	 mass	 spectrometer	
(Applied	 Bio	 systems,	 Foster	 City,	 CA)	 that	 was	 operated	 in	
positive	 ion	mode	with	 turbo	electrospray	 ionization	sources	
(ESI)	(Applied	Biosystems	Inc.,	Foster	City,	CA,	USA).		
	
2.3.	Chromatographic	and	mass	spectrometric	conditions	
	
The	 online	 sample	 cleanup	 was	 achieved	 on	 a	 Security	
Guard	column	(C18,	4	×	3	mm,	5	μm,	Phenomenex,	Torrance,	
CA,	USA).	The	chromatographic	separation	was	performed	on	
a	 Luna	 analytical	 column	 (C18(2),	 50	 ×	 2.0	 mm,	 5	 µm,	
Phenomenex,	Torrance,	CA,	USA).		
Three	pumps	were	used	with	a	10‐place	switching	valve	to	
perform	the	online	sample	cleanup	procedure.	Mobile	phase	A	
(in	pumps	A	&	C)	was	0.1%	 formic	acid	 in	water	 and	mobile	
phase	 B	 (in	 pump	 B)	 was	 0.1%	 formic	 acid	 in	
acetonitrile:	water	 (95:5,	 v:v).	 The	 aqueous	 mobile	 phase	 A	
was	 used	 at	 1	mL/min	 to	 load	 and	 wash	 the	 sample	 on	 the	
guard	 cartridge	 for	1.47	min	and	 then	a	 gradient	 elution	was	
used	 with	 mobile	 phase	 consisting	 of	 0.1%	 formic	 in	 water	
(solvent	 A)	 and	 acetonitrile:	 water	 in	 the	 ratio	 of	 95:5	 (v:v)	
(solvent	B).	The	elution	gradient	was	as	follows:	started	from	
10%	B	and	kept	for	1	min	then	raised	the	precent	of	B	to	70%	
within	 1	 min,	 maintained	 at	 70%B	 for	 another	 1.5min	 and	
retained	back	to	10%B	at	3.51	min.	The	 total	run	time	was	5	
min	with	 a	 total	 flow	 rate	 of	 0.2	mL/min.	 The	detection	was	
made	 with	 electrospray	 ionization	 operating	 at	 positive	 ion	
mode	 and	 the	 tandem	 spectrometer	 was	 operated	 in	 the	
multiple	 reaction	 monitoring	 (MRM)	 mode.	 The	 mass	
spectrometric	conditions	were	optimized	for	LEV	and	internal	
standard	(IS)	atenolol	by	continuous	 infusion	of	 the	standard	
solutions	 (0.03	µg/min)	 using	 a	 Harvard	 infusion	 pump.	 The	
turbo	ion	spray	temperature	was	maintained	at	400	°C	and	the	
ion	spray	voltage	was	set	at	5000	V.	The	nebuliser	gas	 (GS1)	
and	the	turbo	gas	(GS2)	was	70	psi.	The	curtain	gas	(CUR)	and	
collision	 gas	 (CAD)	 were	 both	 set	 at	 40	 psi.	 Declustering	
potential	 (DP)	 was	 20	 V	 for	 LEV	 and	 38	 V	 for	 IS.	 Collision	
energy	was	27	V	for	LEV	and	40	V	for	IS.	The	MRM	transition	
was	170.9	→	140.8	for	LEV	and	267.3	→	145.1	for	IS.		
	
2.4.	Preparation	of	stock	and	working	solution	
	
Stock	solution	of	LEV	was	prepared	by	dissolving	5.00	mg	
of	 LEV	 in	 10	mL	 of	 water,	 while	 stock	 solution	 of	 IS	 was	
prepared	by	dissolving	5.00	mg	in	least	amount	of	MeOH	and	
make	 up	 to	 10mL	 with	 water.	 The	 solutions	 were	 stored	 at	
4	°C.	 Standard	 working	 solutions	 at	 various	 concentrations	
were	 prepared	 freshly	 by	 diluting	 of	 appropriate	 aliquots	 of	
stock	 solution	with	water.	Working	 IS	 solution	was	prepared	
by	 diluting	 stock	 solution	 to	 obtain	 500	 ug/mL	 final	
concentration.		
2.5.	Preparation	of	calibration	standards	and	quality	
control	(QC)	samples		
	
The	calibration	standards	in	human	plasma	were	prepared	
by	 spiking	 50	 µL	 of	working	 standard	 solution	 into	 50	 µL	 of	
blank	 plasma	 to	 achieve	 the	 concentration	 range	 of	 1‐100	
µg/mL.	 QC	 samples	 were	 prepared	 at	 three	 concentration	
levels	 (5.0,	 37.5	 and	 75.0	µg/mL)	by	 spiking	 the	 appropriate	
working	standard	solutions	into	human	blank	plasma	(50	µL).	
	
2.6.	Sample	preparation	
	
Sample	 preparation	 was	 performed	 by	 protein	
precipitation	 with	 acetonitrile.	 An	 aliquot	 of	 50	 µL	 plasma	
sample	QC	samples,	or	clinical	plasma	samples	(blank	plasma	
in	 case	 of	 standard)	 was	 mixed	 with	 50	μL	 of	 IS	 working	
solution	and	100	µL	of	acetonitrile.	After	vortex‐mixing	for	10	
s	and	centrifuging	at	1000	×	g	for	10	min,	the	supernatant	was	
transferred	 into	 HPLC	 vial	 and	 10	 µL	 was	 injected	 to	 the	
instrument.		
	
2.7.	Method	validation	
	
2.7.1.	Selectivity	and	matrix	effect	
	
The	selectivity	of	 the	method	was	evaluated	 for	potential	
endogenous	 interferences	 for	 LEV	 by	 analysing	 six	 different	
batches	 of	 human	 blank	 plasma.	 A	 peak	 or	 response	 at	 the	
respective	retention	times	for	LEV	and	IS	with	a	signal	to	noise	
ratio	(S/N)	of	less	than	3:1	was	considered	to	be	insignificant.	
Matrix	effect	was	evaluated	by	comparing	peak	area	of	LEV	in	
spike‐after	 preparation	 samples	 with	 that	 in	 neat	 solution.	
Two	 difference	 concentrations	 were	 evaluated	 with	 five	
samples	at	each	level.		
	
2.7.2.	Linearity	and	lower	limit	of	quantification	(LLOQ)	
	
Nine	 non‐zero	 calibration	 standards	 at	 concentrations	 of	
1.00,	1.56,	3.12,	6.25,	12.50,	25.00,	50.00,	80.00,	100.00	µg/mL	
were	 prepared	 freshly	 for	 each	 run	 and	 analysed	 in	 three	
separate	 runs.	 Calibration	 curves	 were	 obtained	 by	 linear	
regression	 of	 the	 peak	 area	 ratios	 of	 LEV	 to	 IS	 against	 the	
corresponding	concentrations	using	a	weighting	factor	of	1/χ2	
(reversed	square	of	the	concentration).	The	LLOQ	was	defined	
as	 the	 lowest	 concentration	 in	 the	 standard	 curve	 with	 a	
precision	of	less	than	20%	and	accuracy	80‐120%.	Deviations	
from	 the	 nominal	 concentrations	 should	 be	within	 ±15%	 for	
the	other	concentrations.	
	
2.7.3.	Accuracy	and	precision		
	
The	 intra‐day	 accuracy	 and	precision	was	determined	by	
analysing	 QCs	 at	 three	 concentration	 levels	 using	 a	 freshly	
prepared	 calibration	 curve	 on	 the	 given	 day.	 Additional	 QC	
samples	were	also	analysed	on	 five	different	days	 in	order	 to	
assess	 inter‐day	 accuracy	 and	 precision.	 Precision	 was	
represented	 as	 percentage	 of	 relative	 standard	 deviations	
(RSD%)	 while	 accuracy	 was	 expressed	 as	 the	 mean	 of	 the	
measured	 concentrations	 as	 a	 percentage	 of	 the	 nominal	
concentration.	
	
2.7.4.	Stability	test	
	
The	 post‐preparative	 stability	 in	 the	 autosampler	 at	 4	 °C	
was	 determined	 by	 injecting	 preparations	 of	 processed	
samples	 for	 up	 to	 24h	 after	 the	 initial	 injection.	 Short‐term	
stability	 in	 plasma	 (3h	 bench	 storage)	 was	 determined	 at	
ambient	 temperature	 (24±3	 °C)	 at	 concentrations	 of	 QC	
samples.	The	stability	was	also	tested	after	three	freeze/thaw	
cycles	using	the	concentrations	of	QC	samples.		
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(a)	
	
(b)
	
	
(c)	
	
Figure	2.	(a)	Representative	extracted	ion	chromatogram	(XIC)	of	blank	plasma;	(b)	calibration	standard	samples	at	LLOQ	level	and	(c)	calibration	standard	
samples	at	ULOQ	level.	
	
 
 
The	 samples	were	 stored	 at	 ‐80	 °C	 between	 freeze/thaw	
cycles,	and	then	they	were	thawed	by	allowing	them	to	stand	
at	 room	 temperature	 for	approximately	30	min.	The	samples	
were	then	returned	to	freezer	for	24	h.		
	
2.8.	Application		
	
This	method	was	applied	to	monitor	plasma	level	of	LEV	in	
single	case	study	for	patient	taking	toxic	dose	of	LEV.	Patient’s	
samples	 (plasma)	 were	 stored	 at	 ‐80	 °C	 until	 analysis.	 All	
patient	identifiers	had	been	removed.	
	
	
3.	Results		
	
3.1.	LC‐MS/MS	optimization		
	
The	protonated	forms	of	the	analyte	and	internal	standard	
molecule	 [M+H]+	 (m/z	 170.9)	 and	 (m/z	 267.3),	 respectively,	
were	found	to	be	the	dominate	 ion	in	Q1	scan	and	were	used	
to	 generate	 a	 product	 ion	 spectrum.	 For	 MRM,	 the	 most	
abundant	 fragment	 ion	 of	 the	 analyte	 and	 internal	 standard	
(m/z	140.8)	 and	 (m/z	145.0),	 respectively,	was	 selected	 and	
the	 fragmentation	 conditions	 were	 optimized.	 Chromato‐
graphic	 separation	 was	 obtained	 with	 good	 resolution	
between	 (LEV)	 and	 IS.	 There	 is	 no	 interference	 between	
plasma	ingredients	and	analyte	as	well	as	IS,	Figure	2a‐c.	
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Table	1.	Intra‐	and	inter‐day	accuracy	(%	of	nominal	concentration)	and	precision	(%RSD)	of	LEV	in	human	plasma.	
Nominal	
concentration	
(ng/mL)	
Intra‐day	
accuracy	(%)	
Inter‐day	
accuracy	(%)	
Intra‐day	
precision	(%RSD)	
Inter‐day	
precision	(%RSD)	
Intra‐day	
precision	
(Mean±SD)	
Inter‐day	
precision	
(Mean±SD)	
5.0	 102.7	 97.7	 6.7 4.6 102.7±6.88	 97.7±4.49
37.5	 102.8	 104.7	 9.2 11.6 102.8±9.45	 104.7±12.1
80.0	 102.4	 112.6	 9.4	 1.4	 102.4±9.6	 112.6±1.57	
	
	
Table	2.	Stabilities	of	LEV	in	human	plasma	quality	control	samples	(n	=	3).	
Analyte	 Nominal	concentration	(ng/mL)	 %	Loss/gain	in	stability	study	(Accuracy)
Post‐preparative	 Freeze‐thaw	 Short	term	
LEV	 5.0	 ‐11.2% +3.9% ‐2.5%	
37.5	 ‐10.5%	 +2.0%	 +1.4%	
75.0	 +4.0% +13.4% +1.2%	
	
	
3.2.	Method	validation		
	
3.2.1.	Selectivity	and	matrix	effect		
	
Six	 different	 batches	 of	 blank	 human	 plasma	 were	
screened	 for	 any	 false	 positive	 MS	 responses.	 No	 significant	
peak	 or	 response	 was	 detected	 at	 the	 retention	 time	 for	
analyte	 and	 IS	 (S/N	 ratio	was	 less	 than	 3:1).	 In	 addition,	 no	
obvious	matrix	effect	was	found	when	comparing	peak	area	of	
LEV	 in	 spike‐after	 preparation	 samples	 with	 that	 in	 neat	
solution.	
	
3.2.2.	Linearity	and	LLOQ	
	
Calibration	curves	were	linear	over	a	concentration	range	
of	 1‐100	 µg/mL	 for	 LEV	 in	 human	 plasma	 with	 an	 average	
correlation	coefficient	of	0.996±0.00257	(n	=	3).	Deviations	of	
measured	from	nominal	concentrations	were	between	‐1.5	 to	
4.5%	 for	 LLOQ	 (1	 µg/mL)	 and	 between	 ‐11	 to	 10%	 for	 the	
other	 concentration	 levels.	 Precision	 was	 3.0%	 at	 LLOQ	 and	
between	2.5	and	8.9%	at	the	remaining	concentration	levels.		
	
3.2.3.	Accuracy	and	precision	
	
Table	 1	 summarizes	 assay	 performance	 data	 for	 LEV	 in	
human	plasma.	The	 intra‐	and	 inter‐day	precision	 (%RSD)	as	
well	as	were	accuracy	in	the	range1.4‐11.6%	and	97.7‐112.6%	
for	 precision(%RSD)	 and	 accuracy	 respectively	 for	 all	 QC	
levels,	thus	meeting	the	requirement	of	within	±15%	[21].		
	
3.2.4.	Stability	test	
	
As	shown	in	Table	2,	LEV	plasma	samples	were	stable	up	
to	 3	 hours	 in	 room	 temperature,	 up	 to	 24	 hrs	 after	 sample	
preparation	 in	 the	 autosampler	 and	 after	 three	 freeze/thaw	
cycles	 as	 the	 relative	 deviation	 were	 within	 ±15%	 for	 all	
analytes	at	different	concentrations.		
	
3.3.	Application		
	
The	developed	method	was	used	for	determination	of	LEV	
concentration	in	plasma	after	oral	 ingestion.	Blood	have	been	
collected	 at	 different	 time	 intervals.	 Plasma	 concentration	 of	
LEV	confirms	that	calibration	range	of	our	method	suitable	for	
toxicological	testing	of	LEV.	
	
4.	Discussions	
	
The	main	use	of	guard	column	is	to	protect	the	analytical	
column	 from	 damage	 without	 notably	 changes	 in	 analyte	
retention	 time.	 In	 this	study	guard	column	was	used	 to	clean	
plasma	extract	 to	obtain	more	sensitivity	of	determination	of	
LEV	 in	 plasma.	 Guard	 cartridge	 is	 a	 relatively	 inexpensive	
consumable;	 this	will	allow	the	replacement	of	 it	 regularly	 to	
keep	 the	 performance	 of	 assay.	 Based	 on	 the	 chemical	
structure,	electrospray	ionization	was	used	for	ion	generation.	
A	 Q1	 full	 scan	 of	 LEV	 was	 performed	 in	 both	 positive	 and	
negative	 mode.	 The	 positive	 mode	 was	 selected	 due	 to	 a	
greater	 sensitivity.	 The	 utilization	 of	 Multiple	 Reaction	
Monitoring	 (MRM)	scan	mode	allow	determination	of	 certain		
compounds	in	presence	of	interfering	compounds	in	plasma	by	
tandem	mass	[22].	
Good	 IS	 should	 resemble	 the	 analytes	 during	 extraction	
and	 compensate	 for	 analytes	 on	 the	 column,	 especially	 with	
LC‐MS/MS,	due	to	matrix	effects	could	produce	poor	analytical	
results.	Several	compounds,	such	as	metformin,	phenibut	and	
atenolol	were	examined;	we	found	that	atenolol	was	the	best.	
During	 method	 development	 different	 mobile	 phase	
compositions	were	 tested	 for	 chromatographic	 separation	 of	
LEV	 and	 IS.	 In	 order	 to	 decrease	 ionization	 of	 LEV	 to	 allow	
more	retention	on	column	and	good	separation	we	use	at	pH	=	
2.5	(using	0.1%	formic	acid).	Acidification	of	mobile	phase	by	
formic	 acid	 enhance	protonation	of	LEV	 reduce	 the	 retention	
time	and	improve	the	peak	shape.	
	
5.	Conclusion	
	
In	summary,	I	have	developed	a	rapid,	accurate	and	robust	
LC‐MS/MS	method	for	quantification	of	LEV	in	human	plasma.	
The	 simplicity	 and	 accuracy	 of	 this	 make	 it	 suitable	 for	
toxicological	studies	as	well	as	therapeutic	drug	monitoring	of	
LEV.	The	uses	of	guard	column	as	sample	cleanup	improve	the	
performance	of	assay;	allow	quantitative	determination	of	LEV	
in	human	plasma.	
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